Display options
Cite
Bekisz J, Baron S, Balinsky C, et al. Antiproliferative Properties of Type I and Type II Interferon. Pharmaceuticals (Basel). 2010;3(4):994-1015doi: 10.3390/ph3040994.
Bekisz, J., Baron, S., Balinsky, C., Morrow, A., & Zoon, K. C. (2010). Antiproliferative Properties of Type I and Type II Interferon. Pharmaceuticals (Basel, Switzerland), 3(4), 994-1015. https://doi.org/10.3390/ph3040994
Bekisz, Joseph, et al. "Antiproliferative Properties of Type I and Type II Interferon." Pharmaceuticals (Basel, Switzerland) vol. 3,4 (2010): 994-1015. doi: https://doi.org/10.3390/ph3040994
Bekisz J, Baron S, Balinsky C, Morrow A, Zoon KC. Antiproliferative Properties of Type I and Type II Interferon. Pharmaceuticals (Basel). 2010 Mar 30;3(4):994-1015. doi: 10.3390/ph3040994. PMID: 20664817; PMCID: PMC2907165.
Copy Download .nbib Format: NLM
Share it on

Pharmaceuticals (Basel). 2010 Mar 30;3(4):994-1015. doi: 10.3390/ph3040994.

Antiproliferative Properties of Type I and Type II Interferon.

Pharmaceuticals (Basel, Switzerland)

Joseph Bekisz, Samuel Baron, Corey Balinsky, Angel Morrow, Kathryn C Zoon

Affiliations

  1. National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.

PMID: 20664817 PMCID: PMC2907165 DOI: 10.3390/ph3040994

Abstract

The clinical possibilities of interferon (IFN) became apparent with early studies demonstrating that it was capable of inhibiting tumor cells in culture and in vivo using animal models. IFN gained the distinction of being the first recombinant cytokine to be licensed in the USA for the treatment of a malignancy in 1986, with the approval of IFN-α2a (Hoffman-La Roche) and IFN-α2b (Schering-Plough) for the treatment of Hairy Cell Leukemia. In addition to this application, other approved antitumor applications for IFN-α2a are AIDS-related Kaposi's Sarcoma and Chronic Myelogenous Leukemia (CML) and other approved antitumor applications for IFN-α2b are Malignant Melanoma, Follicular Lymphoma, and AIDS-related Kapoisi's Sarcoma. In the ensuing years, a considerable number of studies have been conducted to establish the mechanisms of the induction and action of IFN's anti-tumor activity. These include identifying the role of Interferon Regulatory Factor 9 (IRF9) as a key factor in eliciting the antiproliferative effects of IFN-α as well as identifying genes induced by IFN that are involved in recognition of tumor cells. Recent studies also show that IFN-activated human monocytes can be used to achieve >95% eradication of select tumor cells. The signaling pathways by which IFN induces apoptosis can vary. IFN treatment induces the tumor suppressor gene p53, which plays a role in apoptosis for some tumors, but it is not essential for the apoptotic response. IFN-α also activates phosphatidylinositol 3-kinase (PI3K), which is associated with cell survival. Downstream of PI3K is the mammalian target of rapamycin (mTOR) which, in conjunction with PI3K, may act in signaling induced by growth factors after IFN treatment. This paper will explore the mechanisms by which IFN acts to elicit its antiproliferative effects and more closely examine the clinical applications for the anti-tumor potential of IFN.

References

  1. Expert Opin Pharmacother. 2006 Jul;7(10):1273-90 - PubMed
  2. Exp Hematol. 2000 Mar;28(3):244-55 - PubMed
  3. Eur J Cancer. 1993;29A(14):1940-3 - PubMed
  4. Semin Oncol. 2004 Apr;31(2 Suppl 4):66-71 - PubMed
  5. Cancer Res. 1990 Dec 1;50(23):7450-6 - PubMed
  6. J Gen Virol. 1970 Jun;7(3):203-10 - PubMed
  7. Proc Natl Acad Sci U S A. 1984 Mar;81(6):1747-50 - PubMed
  8. Biotherapy. 1997;10(1):1-5 - PubMed
  9. Annu Rev Biochem. 1998;67:227-64 - PubMed
  10. Br J Cancer. 1996 Sep;74(5):670-6 - PubMed
  11. Oncogene. 1999 May 6;18(18):2798-810 - PubMed
  12. J Natl Cancer Inst. 1972 Apr;48(4):1151-4 - PubMed
  13. Nat Med. 2006 Feb;12(2):207-13 - PubMed
  14. Oncogene. 1997 Jan 30;14(4):415-23 - PubMed
  15. Rev Immunogenet. 2000;2(3):374-86 - PubMed
  16. J Exp Ther Oncol. 2002 Sep-Oct;2(5):286-97 - PubMed
  17. Blood. 2001 Oct 1;98(7):2183-92 - PubMed
  18. J Natl Cancer Inst. 2003 Mar 19;95(6):437-48 - PubMed
  19. Acta Paediatr Jpn. 1993 Aug;35(4):361-4 - PubMed
  20. Pathobiology. 1991;59(4):259-63 - PubMed
  21. Eur J Cancer. 2010 Jan;46(2):284-97 - PubMed
  22. Nat Rev Cancer. 2003 Sep;3(9):666-75 - PubMed
  23. J Biol Chem. 1995 Jul 7;270(27):15938-41 - PubMed
  24. Nature. 2009 Apr 16;458(7240):904-8 - PubMed
  25. Am J Pathol. 2006 Jun;168(6):2054-63 - PubMed
  26. Nature. 1985 Feb 14-20;313(6003):597-600 - PubMed
  27. Eur J Cancer. 1980 Apr;16(4):569-73 - PubMed
  28. Genes Dev. 2003 Aug 15;17(16):1969-78 - PubMed
  29. Int J Oncol. 2003 Nov;23(5):1341-6 - PubMed
  30. Apoptosis. 2003 Jun;8(3):237-49 - PubMed
  31. Eur J Cancer. 1980 Sep;16(9):1199-204 - PubMed
  32. Int Immunol. 2007 Jul;19(7):867-79 - PubMed
  33. Proc Soc Exp Biol Med. 1969 Mar;130(3):960-5 - PubMed
  34. Anticancer Res. 1988 Jan-Feb;8(1):145-51 - PubMed
  35. Nature. 1969 Aug 23;223(5208):845-6 - PubMed
  36. Immunology. 2006 Jan;117(1):38-46 - PubMed
  37. Int J Cancer. 1995 May 4;61(3):342-7 - PubMed
  38. Am J Respir Cell Mol Biol. 2006 Jun;34(6):766-74 - PubMed
  39. Crit Rev Oncol Hematol. 2002 Nov;44(2):143-61 - PubMed
  40. Blood. 2000 Sep 15;96(6):2093-9 - PubMed
  41. J Virol. 2000 Feb;74(3):1513-23 - PubMed
  42. Anticancer Res. 1994 Nov-Dec;14(6B):2673-6 - PubMed
  43. Proc Natl Acad Sci U S A. 1993 Jul 1;90(13):6175-8 - PubMed
  44. Proc Natl Acad Sci U S A. 1985 Feb;82(4):1151-4 - PubMed
  45. J Biol Chem. 2000 Sep 8;275(36):27634-40 - PubMed
  46. Cancer Res. 2002 Sep 1;62(17):5069-75 - PubMed
  47. Oncogene. 2002 Feb 14;21(8):1251-62 - PubMed
  48. Eur J Haematol. 1997 Sep;59(3):129-35 - PubMed
  49. Int J Cancer. 1995 Mar 29;61(1):110-4 - PubMed
  50. Hematol Oncol Clin North Am. 2004 Jun;18(3):585-603, viii - PubMed
  51. J Exp Med. 1999 May 3;189(9):1451-60 - PubMed
  52. J Immunol. 1990 May 1;144(9):3643-8 - PubMed
  53. Rev Eur Etud Clin Biol. 1970 Jan;15(1):23-7 - PubMed
  54. Oncogene. 1992 Apr;7(4):783-8 - PubMed
  55. Curr Med Chem. 2007;14(12):1279-89 - PubMed
  56. Nat New Biol. 1972 Jan 12;235(54):48-50 - PubMed
  57. Oncologist. 2003;8(5):451-8 - PubMed
  58. AIDS. 1996 Jun;10(7):804-5 - PubMed
  59. Proc Natl Acad Sci U S A. 1995 May 9;92(10):4562-6 - PubMed
  60. J Biol Chem. 1998 Sep 11;273(37):23659-67 - PubMed
  61. Cancer Res. 2009 Feb 1;69(3):855-62 - PubMed
  62. Cancer Treat Res. 2008;142:193-209 - PubMed
  63. Cancer Res. 1974 May;34(5):1074-8 - PubMed
  64. J Interferon Cytokine Res. 2005 Dec;25(12):780-7 - PubMed
  65. J Immunol. 1997 Mar 1;158(5):2390-7 - PubMed
  66. J Biol Chem. 1999 Jan 8;274(2):571-3 - PubMed
  67. Front Biosci. 2000 Apr 01;5:D479-87 - PubMed
  68. Clin Cancer Res. 2001 Jun;7(6):1821-31 - PubMed
  69. Oncogene. 1998 Apr 23;16(16):2075-86 - PubMed
  70. J Exp Med. 1977 Dec 1;146(6):1511-20 - PubMed
  71. Curr Protein Pept Sci. 2004 Dec;5(6):475-85 - PubMed
  72. Proc Natl Acad Sci U S A. 1999 Nov 23;96(24):13956-61 - PubMed
  73. J Interferon Cytokine Res. 2008 Sep;28(9):553-61 - PubMed
  74. J Biol Chem. 2002 Apr 26;277(17):14408-16 - PubMed
  75. Cell Signal. 2000 Jan;12(1):1-13 - PubMed
  76. Proc Natl Acad Sci U S A. 1992 Jul 15;89(14):6599-603 - PubMed
  77. J Interferon Cytokine Res. 2002 Mar;22(3):295-303 - PubMed
  78. Int J Cancer. 1984 Oct 15;34(4):495-500 - PubMed
  79. J Immunother. 2009 Oct;32(8):803-16 - PubMed
  80. Antimicrob Agents Chemother. 2001 Feb;45(2):553-62 - PubMed
  81. J Interferon Cytokine Res. 2005 Dec;25(12):749-56 - PubMed
  82. J Biol Chem. 1997 Nov 28;272(48):29991-4 - PubMed
  83. J Biol Chem. 2004 Oct 29;279(44):45603-12 - PubMed
  84. Cancer Res. 1987 Oct 1;47(19):5155-61 - PubMed
  85. Cell Immunol. 1983 Dec;82(2):394-402 - PubMed
  86. Lancet. 1959 Sep 12;2(7098):324-5 - PubMed
  87. Cancer Immunol Immunother. 2004 Apr;53(4):363-72 - PubMed
  88. Int J Cancer. 1995 May 4;61(3):348-54 - PubMed
  89. Nat New Biol. 1971 Jul 21;232(29):76-8 - PubMed
  90. Cell Death Differ. 2006 Sep;13(9):1541-53 - PubMed
  91. Proc Natl Acad Sci U S A. 1969 May;63(1):51-7 - PubMed
  92. Exp Hematol. 1999 Aug;27(8):1315-21 - PubMed
  93. Med Oncol. 2001;18(1):3-14 - PubMed
  94. J Reticuloendothel Soc. 1978 Nov;24(5):549-70 - PubMed
  95. FEBS Lett. 1997 Feb 10;403(1):31-4 - PubMed
  96. Ann Ist Super Sanita. 1990;26(3-4):255-61 - PubMed
  97. J Biol Chem. 1997 Jun 27;272(26):16351-7 - PubMed
  98. Mol Cell Biol. 1996 Jul;16(7):3934-44 - PubMed
  99. Blood. 1987 May;69(5):1280-8 - PubMed
  100. Blood. 1998 Oct 15;92(8):2914-23 - PubMed
  101. Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16448-53 - PubMed
  102. Br J Haematol. 1994 Oct;88(2):268-74 - PubMed
  103. Eur J Cancer. 1996 Oct;32A(11):1905-11 - PubMed
  104. Cell Growth Differ. 1997 Mar;8(3):343-52 - PubMed
  105. J Acquir Immune Defic Syndr (1988). 1990;3(12):1159-67 - PubMed
  106. Cell Death Differ. 1999 Aug;6(8):773-80 - PubMed
  107. J Clin Invest. 1997 Dec 1;100(11):2691-6 - PubMed
  108. Cancer Res. 1984 Jun;44(6):2358-62 - PubMed
  109. N Engl J Med. 2006 Jun 15;354(24):2531-41 - PubMed
  110. Blood. 1997 Feb 1;89(3):957-64 - PubMed
  111. J Interferon Cytokine Res. 1997 Mar;17(3):141-3 - PubMed
  112. Eur J Biochem. 1982 May;124(1):131-8 - PubMed
  113. Cell Cycle. 2006 Aug;5(16):1840-6 - PubMed
  114. J Biol Chem. 2004 Jun 4;279(23):24152-62 - PubMed
  115. Biotherapy. 1998;11(4):241-53 - PubMed
  116. Ann N Y Acad Sci. 1976;276:134-45 - PubMed
  117. Virology. 1962 Jun;17:324-34 - PubMed
  118. FEBS J. 2006 Aug;273(16):3698-708 - PubMed
  119. J Immunol. 2006 Jan 1;176(1):309-18 - PubMed
  120. Proc R Soc Lond B Biol Sci. 1957 Sep 12;147(927):258-67 - PubMed
  121. Cancer Cell. 2004 Nov;6(5):485-95 - PubMed
  122. Cancer Invest. 2008 Oct;26(8):860-5 - PubMed
  123. Transplantation. 1976 Mar;21(3):242-6 - PubMed
  124. Blood. 1991 Feb 15;77(4):792-8 - PubMed
  125. J Interferon Cytokine Res. 2007 Feb;27(2):157-63 - PubMed
  126. Pharmacol Ther. 2003 May;98(2):129-42 - PubMed
  127. Virology. 1967 May;32(1):122-7 - PubMed
  128. Blood. 2008 Aug 1;112(3):542-50 - PubMed
  129. J Biol Chem. 2005 Jan 14;280(2):1037-43 - PubMed
  130. Curr Opin Genet Dev. 2002 Feb;12(1):92-7 - PubMed

Publication Types

Grant support